Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352287 · ClinicalTrials.gov registry record · Phase 4
Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT00352287: Completed Phase 4 study, sponsored by Stanford University.
NCT00352287 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00352287, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat. Participants received a combination of two drugs: (1) recombinant human growth hormone (or its placebo) and (2) pioglitazone (or its placebo). We measured the abdominal fat content and blood sugar levels of participants before and after 40 weeks of treatment.
Interventions
- DRUG Recombinant human growth hormone; pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-03 |
| Est. Completion | 2005-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352287
The ClinicalTrials.gov registry entry for NCT00352287 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant human growth hormone; pioglitazone is the first listed.
NCT00352287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00352287 about?
NCT00352287 is a clinical study titled "Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults". The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat. Participants received a combination of two drugs: (1) recombinant human growth hormone (or its placebo) and (2) pioglitazone (or its ...
What is the current status of trial NCT00352287?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2003-03. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00352287?
The interventions under investigation include: Recombinant human growth hormone; pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00352287?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.